Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis.

Lindsay M BuschJunfeng SunXizhong CuiPeter Q EichackerParizad Torabi-Parizi

Published in: Intensive care medicine experimental (2020)

Preclinical studies showing that CPIs add benefit to antibiotic therapy for the common bacterial infections causing sepsis clinically are needed to support this therapeutic approach. Studies should be reproducible across multiple laboratories and include procedures to reduce the risk of bias.

Keyphrases

acute kidney injury
septic shock
intensive care unit
case control
cell therapy
dna damage
cell cycle
mesenchymal stem cells
replacement therapy